Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy

Gynecologic Oncology
Christine S Walsh

Abstract

Almost exactly 20 years after their discovery, the BRCA1 and BRCA2 genes have become the target of the first "personalized" therapy available for patients with ovarian cancer. In December 2014, a poly(ADP-ribose) polymerase (PARP) inhibitor was granted expedited approved by the United States Food and Drug Administration for use in advanced ovarian cancer patients with germline BRCA1/2 mutations who have received three or more prior lines of chemotherapy. This review article will discuss (1) the BRCA1 and BRCA2 genes within the larger context of homologous recombination deficiency; (2) the advances in our understanding of hereditary cancer risk and the dramatic shifts that have occurred in the genetic testing landscape since the landmark 2013 Supreme Court ruling invalidating patents on BRCA1 and BRCA2 genetic testing; and (3) the clinical trials leading to the approval of olaparib, the first in human PARP inhibitor.

References

Apr 25, 2003·Cancer·Ilana CassBeth Y Karlan
Aug 22, 2003·Nucleic Acids Research·Niklas SchultzThomas Helleday
Aug 30, 2003·Oncogene·Kristoffer Valerie, Lawrence F Povirk
May 4, 2004·American Journal of Human Genetics·UNKNOWN CHEK2 Breast Cancer Case-Control Consortium
Oct 29, 2004·Nature Reviews. Cancer·Nicholas TurnerAlan Ashworth
Jun 14, 2006·International Journal of Cancer. Journal International Du Cancer·Jan SteffenZygmut Paszko
Jul 13, 2006·Nature Genetics·Anthony RenwickNazneen Rahman
Aug 24, 2006·Nature Reviews. Molecular Cell Biology·Patrick Sung, Hannah Klein
Jan 4, 2007·Nature Genetics·Nazneen RahmanMichael R Stratton
Jan 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angela ChetritSiegal Sadetzki
Apr 17, 2008·Cancer Research·Elizabeth M SwisherToshiyasu Taniguchi
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Apr 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter C FongStan B Kaye
Aug 31, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Monika GraeserNicholas C Turner
Aug 9, 2011·Nature Genetics·Chey LovedayNazneen Rahman
Oct 4, 2011·Nature Genetics·Thorunn RafnarKari Stefansson
Oct 19, 2011·Proceedings of the National Academy of Sciences of the United States of America·Tom WalshElizabeth M Swisher
Dec 1, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xuesong LiuAlexander R Shoemaker
Mar 29, 2012·The New England Journal of Medicine·Jonathan LedermannUrsula Matulonis
Apr 3, 2012·Nucleic Acids Research·Lumir KrejciXiaolan Zhao
Jun 20, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathryn AlsopGillian Mitchell
Nov 3, 2012·Cancer Research·Junko MuraiYves Pommier
Nov 19, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kathryn P PenningtonElizabeth M Swisher

❮ Previous
Next ❯

Citations

Oct 7, 2015·Cancer·Christine S Walsh
Sep 30, 2015·Seminars in Cancer Biology·Suzanne J Randle, Heike Laman
Jun 1, 2016·Surgical Pathology Clinics·Gillian Mitchell, Kasmintan A Schrader
Sep 5, 2015·Analytical Cellular Pathology (Amsterdam)·Maria Nowacka-ZawiszaWanda M Krajewska
Apr 17, 2016·Breast Cancer Research and Treatment·Kristen S PurringtonFergus J Couch
Apr 27, 2016·Expert Review of Anticancer Therapy·Rachel Nirsimloo, Charlie Gourley
Dec 13, 2016·British Medical Bulletin·Anju Kulkarni, Helena Carley
Nov 15, 2016·Expert Opinion on Therapeutic Patents·Zigao YuanYuyang Jiang
Apr 27, 2017·Critical Reviews in Clinical Laboratory Sciences·Khalid El BairiSaid Afqir
Dec 24, 2015·Current Opinion in Obstetrics & Gynecology·Christine S Walsh, Melissa Hodeib
Jul 12, 2018·AJR. American Journal of Roentgenology·Ailbhe C O'NeillNikhil H Ramaiya
Aug 18, 2018·Expert Review of Clinical Pharmacology·Dan Le, Karen A Gelmon
Feb 22, 2018·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Tara ByrneFiona Furlong
May 12, 2019·Statistical Applications in Genetics and Molecular Biology·Yulan LiangArpad Kelemen
May 18, 2019·Clinical Genetics·Nicola FlaumDafydd G Evans
Nov 8, 2017·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Laurie S StevisonRita M Graze
Jun 4, 2019·The New England Journal of Medicine·Talia GolanHedy L Kindler
Aug 26, 2019·Molecular and Cellular Biochemistry·Maurilio da Silva MorroneJosé Cláudio Fonseca Moreira
Sep 4, 2019·Future Oncology·Christina R WashingtonKathleen N Moore
Oct 28, 2019·Investigational New Drugs·Stergios BoussiosNicholas Pavlidis
Apr 29, 2020·The New England Journal of Medicine·Johann de BonoMaha Hussain
May 5, 2020·American Society of Clinical Oncology Educational Book·Panagiotis A KonstantinopoulosKathleen N Moore
Mar 25, 2020·Oncotarget·Emanuela Dell'AquilaDaniele Santini
Nov 3, 2016·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Miriam DenizLisa Wiesmüller
Sep 1, 2020·Expert Review of Anticancer Therapy·Ritika Halder, Rachna T Shroff
Oct 9, 2015·Current Opinion in Oncology·Geraldine OʼSullivan CoyneShivaani Kummar
Jun 15, 2017·Breast Care·Eric HahnenRita K Schmutzler
Sep 27, 2018·Nature Communications·Donna R WhelanEli Rothenberg
Nov 30, 2019·Insights Into Imaging·Francesco AlessandrinoNikhil H Ramaiya
May 2, 2020·Journal of Assisted Reproduction and Genetics·Ying LiaoLiping Cai
Aug 4, 2018·Annals of Internal Medicine·Shiuh-Wen Luoh, Keith T Flaherty

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.